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Abstract 
 
Serum neuronal autoantibodies, such as those to the NMDA receptor (NMDAR), are 
detectable in a subgroup of patients with psychotic disorders. It is not known if they are 
present before the onset of psychosis or whether they are associated with particular clinical 
features or outcomes. In a case-control study, sera from 254 subjects at clinical high risk 
(CHR) for psychosis and 116 healthy volunteers were tested for antibodies against multiple 
neuronal antigens implicated in CNS autoimmune disorders, using fixed and live cell-based 
assays (CBAs). Within the CHR group, the relationship between NMDAR antibodies and 
symptoms, cognitive function and clinical outcomes over 24 month follow-up was 
examined. CHR subjects were not more frequently seropositive for neuronal autoantibodies 
than controls (8.3% vs 5.2%; OR = 1.50; 95% CI: 0.58 – 3.90; p = 0.40). The NMDAR was the 
most common target antigen and NMDAR IgGs were more sensitively detected with live 
versus fixed CBAs (p<0.001). Preliminary phenotypic analyses revealed that within the CHR 
sample, the NMDAR antibody seropositive subjects had higher levels of current depression, 
performed worse on the Rey Auditory Verbal Learning Task (p<0.05), and had a markedly 
lower IQ (p<0.01). NMDAR IgGs were not more frequent in subjects who later became 
psychotic than those who did not. NMDAR antibody serostatus and titre was associated 
with poorer levels of functioning at follow-up (p<0.05) and the presence of a neuronal 
autoantibody was associated with larger amygdala volumes (p<0.05). Together, these 
findings demonstrate that NMDAR autoantibodies are detectable in a subgroup of CHR 
subjects at equal rates to controls. In the CHR group, they are associated with affective 
psychopathology, impairments in verbal memory, and low IQ: these findings are 
qualitatively and individually similar to core features of autoimmune encephalitis and/or 
animal models of NMDAR antibody-mediated CNS disease. Overall the current work 
supports further evaluation of NMDAR autoantibodies as a possible prognostic biomarker 
and aetiological factor in a subset of people already meeting CHR criteria. 
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Introduction 
 
Neuronal surface autoantibodies (NSAbs) have been identified in blood samples from a 
minority of patients with psychotic disorders and several other unrelated neurological and 
psychiatric conditions (1-3). These autoantibodies target cell-surface proteins, such as the 
NMDA receptor (NMDAR), GABAA or GABAB receptor, AMPA receptor, LGI1 or CASPR2 or 
intracellular proteins, such as GAD. When present in CSF, these IgG-subclass cell-surface 
targeting antibodies are considered pathogenic and associate with severe autoimmune 
encephalopathy syndromes which can present with varied psychiatric features, particularly 
in the case of NMDAR antibody encephalitis, plus impaired cognitive function and 
pathological changes centred around limbic brain regions  (4-8). Estimates of the prevalence 
of NSAbs in patients with psychosis vary depending on the age, condition studied and the 
assay used. Live cell-based assays (CBAs) consistently detect higher rates than fixed CBAs, 
and fixed CBA positivity rates vary widely (1, 9-11). Therefore, the clinical relevance of these 
serum-only antibodies remains unclear. 
 
At present, there are no data on whether NSAbs are present prior to the onset of psychosis 
and, if so, whether they predict clinical outcomes. People at clinical high risk (CHR) for 
psychosis experience subthreshold psychotic symptoms, display memory impairments  (12) 
and show alterations in the structure of limbic brain areas (12-14), findings that show a 
partial resemblance to those seen in NMDAR antibody mediated encephalitis (4, 15-17).  
 
Outside  of the autoimmune encephalitis context there is increasing evidence that NMDAR 
antibodies may be associated with cognitive impairment (e.g. in cancer (18, 19), or following 
viral encephalitis(20)) but this association has not been examined in the context of 
psychosis-spectrum disorders. In patients who have developed psychosis, most studies have 
not found clinically significant differences in symptom profile between seropositive and 
seronegative patients (3, 9, 10, 21), raising potential doubts over their pathogenic 
relevance. However, in vitro, serum NMDAR antibodies from patients with psychosis disrupt 
receptor dynamics (22, 23) and function (9, 24), suggesting that the antibodies have 
pathogenic potential at a molecular level.  
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It is known that NR1-specific intrathecal B cells – which have not been reported in 
psychiatric disorders – are a hallmark of NMDAR-antibody encephalitis (25) and that 
circulating B cells can produce these antibodies (26). The clinical significance of serum 
autoantibodies may depend on the presence of additional factors, such as blood-brain 
barrier (BBB) disruption (9, 27), which could allow them access to the CNS. There is 
widespread evidence for BBB disruption in psychotic disorders (28), although human studies 
are limited by the requirement for CSF samples or the use of proxy clinical markers such as a 
history of brain injury. One such marker is the astrocytic calcium-binding protein S100B 
which is elevated in schizophrenia (28-31), and can be measured in serum samples 
alongside autoantibodies. 
 
If autoantibodies to the NMDAR play an aetiological role in some cases of psychosis, one 
would expect that they would be present before the full clinical expression of the disorder. 
10-35% of patients with CHR may subsequently develop psychosis, with the proportion 
varying between samples (32, 33), and there is an unmet clinical need for biomarkers that 
can predict which individuals will later become psychotic (34). Therefore, we sought to 
address this by investigating various NSAbs in people who are at CHR for psychosis and 
examining the relationship between NMDAR antibodies and clinical outcomes, cognitive 
function and psychopathology in CHR subjects. 
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Materials and methods 
 
Samples 
 
Sera were taken from 254 subjects from the EU-GEI high-risk study who met the PACE 
criteria for the CHR state (35), and from 116 healthy controls (HC). CHR subjects were 
recruited from 11 centres (London, Amsterdam, The Hague, Copenhagen, Vienna, Basel, 
Cologne, Melbourne, Paris, Barcelona, and São Paulo) and were reassessed at a time point 
as close to 12 and 24 months as possible. Exclusion criteria were presence of a current or 
past psychotic disorder, symptoms relevant for inclusion being explained by a medical 
disorder or drugs or alcohol dependency or IQ < 60.  
 
116 HC subjects, frequency matched by age and sex, were recruited from the EU-GEI high-
risk study (n=55), and the South East London Community Health (SELCOH) study (36) (n = 
61). HCs from the EU-GEI study were excluded if they met criteria for the CHR state, while 
HCs from SELCOH were excluded if they screened positive on the Psychosis Screening 
Questionnaire  (37). Ethical approval for the study was obtained from the local research 
ethics committees at each of the sites. All participants provided written informed consent. 
 
All serum samples were stored at -80 degrees Celsius until assayed and tested blind to case-
control status. 
 
Phenotype data 
 
All subjects completed a sociodemographic schedule. Baseline psychopathology was 
assessed using the Comprehensive Assessment of At-Risk Mental States (CAARMS) (38), 
Brief Psychiatric Rating Scale (BPRS) (39), Scale for the Assessment of Negative Symptoms 
(SANS) (40), Young Mania Rating Scale, (YMRS) (41), and the Montgomery-Åsberg 
Depression Rating Scale (MADRS) (42). The Rey Auditory Verbal Learning Task (43) was used 
to assess verbal memory function and IQ was estimated using the shortened Wechsler Adult 
Intelligence Scale III (44). Overall social functioning was assessed using the Global 
Assessment of Functioning (GAF) scale. Participants were invited for face-to-face follow-up 
meetings at 1 year and 2 years after baseline. Where face-to-face meetings were not 
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possible, participants were followed up for 2 years using available clinical records, and this 
follow-up was extended when additional clinical data was available. 
 
Immunoassays  
 
Sera were tested for antibodies of the IgG, IgA and IgM subtypes to 32 different substrates 
(see supplementary appendix 1 for a full list), by indirect immunofluorescence on cell-based 
assays using fixed recombinant HEK293 cells and on frozen sections of rodent and monkey 
brain tissue (hippocampus and cerebellum) at Euroimmun AG, Lübeck, Germany, as 
described previously (45)). 
 
Live CBA autoantibody testing for the detection of IgG antibodies to NMDAR was performed 
using HEK293 cells (European Collection of Authenticated Cell Cultures (ECACC), Public 
Health England) at the Nuffield Department of Clinical Neurosciences, University of Oxford 
as described previously (46) with some modifications. Specifically, intensity of fluorescence 
of each sample was rated on a semi-quantitative visual scoring system of 0-4. Scores of 0 
and 1 were rated as negative, 1.5 as low positive and 2-4 as positive. All positive samples 
were confirmed at dilutions of 1:20, 1:100 and 1:500 using an IgG-Fc specific secondary 
antibody (goat antihuman Fc IgG; Thermo Scientific 31 125), then tested for non-specific 
binding using HEK293 cells that had been transfected with another antigen (dopamine D2 
receptor). The titre of the antibody was given as the dilution of serum giving a score of 1. 
IgG positive samples were tested in the Oxford laboratory for binding to live, cultured rat 
hippocampal neurons as described previously (47). All cell lines are regularly tested for 
Mycoplasma contamination using immunofluorescence. 
 
Levels of S100B, a putative marker of blood-brain barrier disruption, were assessed using a 
chemiluminescence assay (Diasorin). High-sensitivity C-reactive protein (hsCRP) was 
measured as a general marker of systemic inflammation, using high sensitivity enzyme 
immunoassays as previously described (48). 
 
Neuroimaging analysis 
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MR Images were acquired using the ADNI-2 T1 weighted volumetric sequence 
(http://adni.loni.usc.edu/methods/documents/mri-protocols/) from 160 CHR subjects on 3T 
scanners . The ADNI-2 sequence has been specifically developed for multicentre studies and 
has been optimised to give similar contrast across MRI scanners. Nevertheless, the scanner 
was modelled as a factor in the statistical analysis to control for this. T1 weighted volumes 
were and preprocessed using Freesurfer version 6.0.0, using a standard pipeline for 
quantitation of subcortical volumes (described in full on the FreeSurferWiki page 
(https://surfer.nmr.mgh.harvard.edu/fswiki). First, intensity correction and skull stripping 
were performed, followed by segmentation of grey and white matter along with 
segmentation of subcortical structures in which subject scans are warped to a training set 
atlas and individual voxels labelled using a Gaussian classifier analysis, yielding maps of deep 
grey matter, white matter, and CSF structures.  
 
Analyses were performed on Freesurfer’s subcortical segmentation output volumes and 
estimates of total intracranial volumes. Analysis was a priori restricted to the hippocampus 
and the amygdala (both bilaterally), as these are the areas that are predominantly affected 
in autoimmune encephalopathies associated with NSAbs, and these areas have been 
independently linked to the later onset of psychosis in neuroimaging studies of clinical high-
risk populations (49, 50).  
 
 
Statistical analysis 
 
Statistical analyses were performed using SPSS 23. Demographic variables were compared 
between cases and controls and between seropositive and seronegative CHR subjects with 
independent samples t-tests and Mann-Whitney U tests for continuous variables, and chi 
square and Fisher’s exact tests for categorical data. Based on previous work on neuronal 
autoantibody prevalence in first episode psychosis populations(10), sample sizes were 
selected to have statistical power to detect differences. 
 
For symptom and cognitive scales analyses of variance was performed within the General 
Linear Model with NMDAR antibody status (positive or negative), gender and ethnicity as 
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factors and with age as covariate, after homogeneity of variance was confirmed. Given the 
polymorphic psychiatric presentation in NMDAR antibody encephalitis (7, 51) we aimed to 
look at associations with a broad range of psychopathology rather than restricting analyses 
to any one symptom domain or dimension. In addition to total scores for the CAARMS 
(whole instrument score), YMRS, MADRS and SANS, a positive symptoms factor was 
computed based on the BPRS components analysis of Dingemans et al. (52).  
 
For dichotomous outcome measures (transition, nonremission from CHR state), logistic 
regression was performed with NMDAR antibody status (positive or negative), age, gender 
and ethnicity as covariates. 
 
To compare subcortical ‘limbic’ volumes between seropositive and seronegative CHR 
subjects multivariate analysis of variance with NSAb status (positive or negative), MRI site, 
gender and ethnicity as factors, and total intracranial volume (TICV) and age as covariates, 
was performed in the General Linear Model. All main effects were included in our models 
and the analysis of interactions was a priori limited to the interaction between NSAb status 
and S100B status.  
 
Significance threshold was set to p < 0.05; mean ± sd presented. Due to the exploratory 
nature of the analyses, significance values are given for two-tailed tests where applicable 
and uncorrected for multiple comparisons.
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Results 
 
Participants 
 
Demographic and clinical information is presented in Table 1. Cases and controls differed in 
ethnicity, with fewer black participants in the CHR group (8.7%) than in the healthy control 
group (20.7%). The groups did not differ on any other demographic variable. There was no 
difference in mean serum S100B level between CHR subjects and controls (p = 0.833); CHR 
subjects had slightly higher baseline inflammation as indexed by hsCRP (p = 0.048). Smoking 
and antipsychotic usage was more frequent in cases than in controls. 
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Prevalence of NSAbs detected using commercial, fixed CBA and live CBA 
 
Using commercial, fixed assays, NSAbs were detected in 21 (8.3%) CHR subjects and 6 (5.2%) 
of matched, healthy controls (OR = 1.50; 95% CI: 0.58 – 3.90; p = 0.401). Prevalence did not 
differ by site (p = 0.800). IgG was the most commonly detected antibody isotype (48.1%) 
followed by IgA (33.3%) and IgM (22.2%). Isotype distribution did not differ between CHRs 
and HCs (IgG: p = 1.000; IgA: p = 0.283; IgM: p = 0.670). See Figure 1c for distribution of all 
NSAb targets. NMDAR was the most commonly detected antigen in the CHR group (n= 11 
[4.3%]; comprising IgG = 1 [0.4%], IgA = 6 [2.4%] and IgM = 4 [1.6%]) and in the HC group (n= 
2 [1.7%]; comprising IgG = 1 [0.9%], IgA = 0 and IgM = 1 [0.9%]) (Figure 1d). There was no 
difference in overall NMDAR antibody seroprevalence between the CHR and HC groups (p= 
0.36). Although NMDAR antibody isotype distribution was not different between the two 
groups (IgG: p = 0.529; IgA: p = 0.183; IgM: p = 1.000), IgA NMDAR antibody seropositivity 
was seen in 6 CHR subjects but not in any HC.  
 
On fixed CBAs, titres to specific antigens ranged from 1:10 to 1:320 in CHR subjects and 
from 1:32 to 1:320 in HCs (Figure 1e), but none of these bound brain tissue slices on 
immunohistochemistry conducted in the same laboratory. However, 11 of 12 (91.7%) NSAb 
IgG seropositive samples bound cultured rat hippocampal neurons, with three samples 
showing strong binding. Serum from seven subjects (5 CHR subjects, 2 HCs) had IgG, IgA or 
IgM antibodies which bound cerebellum or hippocampus sections (titre 1:32 to 1:320) 
without antigen-specific antibodies detected. No subjects were seropositive for more than 
one antigen on fixed CBA.  
 
Since studies that have used live CBA to detect NMDAR IgG in psychotic patients and 
controls have tended to yield greater seropositivity rates (23) and find case-control 
differences (10, 11, 22), indicating greater analytical sensitivity, we retested all samples for 
NMDAR IgG using a live CBA (Figure 2a). Live CBA detected a significantly higher prevalence 
of NMDAR IgG antibodies in the total cohort than did fixed CBA (19 (5.1%) IgG seropositive 
subjects on live CBA vs 2 (0.5%)) on fixed CBA: p= 0.0001), but were found similarly in 5.1% 
of CHR cases and 5.2% of HCs (p= 1.000). Prevalence did not differ by site (p = 0.145). Titres 
ranged from 1:30 to 1:750 in CHR subjects and from 1:40 to 1:500 in HCs (Figure 2b). The 
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two subjects who were seropositive for NMDAR IgG on fixed CBA were also seropositive on 
live CBA.  
 
17 of 19 samples which were NMDAR IgG seropositive on live assays were tested for binding 
to cultured rat hippocampal neurons: 10 of 17 (58.8%) samples bound neurons, with no 
samples showing strong binding. All four samples with a CBA titre of 1:250 or over bound 
neurons; of the 13 samples with lower titres, six (46.2%) bound neurons. IgG titre on CBA 
and hippocampal binding intensity score were positively correlated (r = 0.491; p = 0.048). 
 
There were no age, sex, ethnicity or smoking status differences between seropositive and 
seronegative subjects (table 2). S100B and hsCRP levels did not differ between seropositive 
and seronegative CHR subjects, for any NSAb or for NMDAR antibodies measured using 
either assay (table 2) . 
 
There were no associations between antibody serostatus and self-reported medical history 
including neurological disorder, autoimmune disorder, head trauma, cancer, history of 
surgical procedures, CNS infection or serious infection (supplemental table 1). Notably the 
only subject that had had a CNS infection (meningitis) was seropositive for NMDAR IgG on 
live assay.
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Clinical outcomes of CHR subjects 
 
Of the 254 CHR subjects from whom serum had been collected and tested for NSAbs, 49 
(19.3%) developed a psychotic illness in the follow-up period. The subjects who transitioned 
to psychosis did not differ from those who did not transition in age or gender (Supplemental 
Table 2).  
 
Of the subjects who transitioned to psychosis, 1 (2.0%) was seropositive for NMDAR 
antibodies on fixed CBA and 3 (6.1%) were seropositive for NMDAR IgG on live assay at 
baseline; of 205 CHR subjects who did not transition to psychosis, 10 (4.9%) were 
seropositive on fixed assay and 10 (4.9%) were seropositive on live assay (Supplemental 
Table 3). In logistic regression analyses, NMDAR antibody serostatus at baseline did not 
predict later transition to psychosis or nonremission from the CHR state, regardless of the 
assay used (fixed or live CBA) for antibody detection (Supplemental Tables 4-7).  
 
Scores of functioning were assessed in CHR subjects at the assessment timepoints closest to 
two years after baseline. Mean change in GAF scores was negative (indicating worsening 
function) for seropositive subjects (live assay), and positive (indicating improvement) in 
seronegative subjects; in multiple regression analyses NMDAR antibody seropositivity was 
significantly associated with change in GAF disability scores (Supplemental Table 8). There 
was a significant negative correlation between NMDAR IgG titre (live assay) and change in 
GAF disability scores (Spearman’s rho = -0.542; p = 0.024), with higher titre subjects showing 
a more negative change in GAF scores, indicating deteriorating function. 
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Cognitive associations of NMDAR antibody seropositivity in CHR subjects 
 
Total RAVLT immediate recall score was lower in CHR subjects seropositive for NMDAR 
antibodies on fixed CBA compared to seronegative CHR subjects (p = 0.030). These 
differences became more substantial after controlling for total CAARMS score (p = 0.007), 
suggesting that the relationship with auditory verbal memory was not simply secondary to 
an effect of the severity of psychopathology (Table 3).  
 
In order to explore whether the association with cognitive impairment was specific to verbal 
memory function, we then compared IQ (estimated using the WAIS-III) in seropositive and 
seronegative subjects. Mean WAIS-III IQ in NMDAR antibody seropositive CHR subjects was 
almost 15 points lower than that in seronegative CHR subjects (p = 0.010). This group 
difference also remained significant after controlling for total CAARMS score (p = 0.008) 
(Table 3). Both effects appeared to be driven by IgA/M antibodies: after restricting the 
analysis to IgA/M seropositive subjects only, both AVLT immediate recall (p=0.011) and 
WAIS-III estimated IQ (p= 0.018) remained significantly impaired in seropositive subjects. 
 
In fact, within the total CHR sample (n=254), only 9 subjects had an IQ below 70 (the 
threshold for a diagnosis of intellectual disability) but 3 of these CHR subjects (33%) were 
seropositive for NMDAR antibodies. Subjects who were NMDAR IgG seropositive on live CBA 
did not differ from seronegative subjects on measures of cognition including AVLT 
immediate recall (p = 0.337) and IQ (p = 0.796).  
 
Symptomatic associations of NMDAR antibody seropositivity in CHR subjects 
 
Nine of 13 (69.2%) subjects who were seropositive for NMDAR antibodies on live assay met 
DSM-IV criteria for current depressive episode, compared to 31.2% of seronegative subjects 
(p = 0.012). Rates of other DSM-IV diagnoses did not differ according to serostatus. There 
was no difference in the rates of specific DSM-IV diagnoses between NMDAR antibody fixed 
CBA seropositive and seronegative subjects (supplemental table 9).  
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While symptom severity scores were not significantly different between seropositive and 
seronegative subjects for most symptom domains when looking at antibodies detected 
using either assay, MADRS scores were borderline significantly higher in CHR subjects 
seropositive on live CBA (p = 0.051), indicating greater depression symptom severity. Across 
the whole CHR cohort, MADRS scores were weakly correlated with NMDAR IgG (live CBA) 
titre (Spearman’s rho = 0.167; p = 0.009). 
 
There was no association between NMDAR antibody serostatus and CHR subtype 
(vulnerability group, APS or BLIPS) (fixed CBA: p = 0.316; live CBA: p = 0.865), although the 
numbers of subjects in the vulnerability (n = 41) and BLIPS (n = 16) subgroups were small. 
 
Association between blood-brain barrier disruption and symptoms 
 
In order to assess the possible role of blood-brain barrier disruption as a moderating 
variable for the associations of NMDAR serostatus with symptom measures, we performed 
a preliminary (due to small n in the seropositive groups) analysis of the association between 
serum S100B levels and symptom scores in NMDAR antibody seropositive and seronegative 
groups. In subjects for whom NMDAR IgG were detected using live CBA, positive 
associations between S100B and symptom severity at baseline were observed for total BPRS 
score and for negative symptoms. In the seronegative group, modest negative associations 
between S100B and symptom severity were observed for multiple symptom scales 
(supplementary table 10). 
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Longitudinal NSAb serostatus 
 
179 follow-up serum samples were available on 120 CHR subjects (modal interval between 
baseline and repeat blood sample: 12 months). Baseline serostatus was predictive of follow-
up serostatus i.e. subjects who were seropositive at baseline were more likely than subjects 
who were seronegative at baseline to be seropositive at follow-up. In total, of 109 CHR 
subjects who were seronegative at baseline and who had blood taken at subsequent visits, 9 
(8.3%) were seropositive at subsequent visits (i.e. had new neuronal antibodies detectable). 
Of 11 subjects who were seropositive at baseline, 4 (36.4%) were still seropositive on at 
least one subsequent visit (p = 0.018). In 3 of these 4 subjects (75%), NSAbs detectable at 
follow-up were to the same antigen and of the same isotype. 
 
None of the four subjects with persistent antibodies (i.e. NSAbs detectable at baseline and 
at a subsequent timepoint) became psychotic during follow-up. Only one of 9 subjects who 
developed de novo NSAbs at follow-up became psychotic: this subject developed NMDAR 
IgM antibodies (1:10) a year after initial assessment, having been seronegative at baseline; 
he went on to transition to psychosis a year later, but no blood samples were available at 
the time he became psychotic or afterwards.  
 
Of 5 subjects who had NMDAR antibodies detectable at baseline and on whom follow-up 
samples were available, two (40%) had NSAbs at one or more follow-up point. One case 
with NMDAR IgA antibodies (1:32) at baseline had IgG antibodies at visit 2 (12 months) 
which bound hippocampus and cerebellum (1:100) but no NMDAR-specific antibodies 
detectable, and at visit 4 (24 months) had no antibodies at all detectable. One case with 
NMDAR IgM antibodies at baseline (1:100) had NMDAR IgM antibodies (1:100) detectable at 
visit 3. Neither of these cases developed psychosis. 
 
Of 11 CHR subjects on whom serum was taken at the time of transition to psychosis, none 
were seropositive.  
 
Limbic volumes in NSAb seropositive CHR subjects 
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Because only a small number of the CHR subjects who were NMDAR antibody seropositive 
had also had an MRI scan (n=5), we investigated the relationship between autoantibodies 
and MRI measures in subjects who were seropositive for any NSAb (n=11). CHR subjects 
who were seropositive for NSAbs had larger amgydala volumes (p = 0.048) than 
seronegative CHR subjects (n=148). There were no group differences in hippocampal 
volume (supplementary table 11). 
 
 
Discussion 
 
Summary of results 
 
This is the first study of CNS autoantibodies in people at CHR for psychosis. We found an 
overall seroprevalence of 8.3%, indicating that NSAbs are detectable in a minority of these 
individuals. The NMDAR was the most common target antigen and NMDAR IgGs were more 
sensitively detected with live versus fixed CBAs. The prevalence was not significantly greater 
than in HCs, mirroring findings from recent studies that have found similar case-control 
seroprevalence rates in patients with psychosis and other psychiatric and non-psychiatric 
disorders (1, 21, 53). NMDAR antibody seropositivity was not associated with the 
development of a psychotic disorder, which was our main outcome of interest, but was 
associated with a deterioration in disability-associated functional status. Within the CHR 
sample, NMDAR antibody seropositivity was associated with impaired verbal memory 
performance, lower IQ and with depressive symptoms. Exploratory MRI analysis indicated 
that NSAb seropositivity was associated with increased amygdala volume.  
 
Relevance of NSAbs in CHR subjects 
 
The combination of impaired cognitive function, severe affective psychopathology (46, 51, 
54) and increased volume of limbic brain regions (55-58) bears some resemblance to (but is 
less severe than) the pattern of findings seen in the acute stages of many autoimmune 
encephalopathies. This suggests that NMDAR antibodies, and possibly other NSAbs, could 
play an analogous, but not necessarily identical, role in the pathophysiology of some 
patients who present with psychiatric symptoms (59). This would be consistent with recent 
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evidence that NMDAR antibodies isolated from psychiatric patients have pathogenicity in 
vitro and in vivo (9, 22, 24).  
 
The reductions in verbal memory performance in NMDAR antibody positive subjects are 
reminiscent of those seen in NMDAR encephalitis, and were of a comparable magnitude 
(19). It is notable however that seropositive CHR subjects did not show other features of 
autoimmune encephalopathies, such as seizures or frank movement disorders. Neurological 
soft signs were not assessed in the present study, but subtle movement signs have been 
observed in a proportion of CHR subjects (60-62) and have been associated with NMDAR 
antibody seropositivity in patients with psychosis (9).  
 
Furthermore, NMDAR-antibody encephalitis is classically associated with a polymorphic 
affective psychosis with catatonic features (7), which is broader than the phenotypic 
associations of seropositivity that we observed. However a rodent model involving the 
intraventricular administration of NMDAR antibodies generated a cognitively impaired, 
anxious and depressive phenotype (63), which is consistent with our findings of an 
association between NMDAR antibodies and MADRS scores and current depressive episodes 
in CHR subjects. It has been suggested that the multifaceted symptomatology of NMDAR 
encephalitis represents more than the effects of the NMDAR antibody at the synapse, and 
that additional immune and non-immune factors help shape clinical presentation. Most 
passive immunisation animal models do not recapitulate a full encephalopathic phenotype, 
instead showing convergence around a more restricted set of symptoms which could be 
conceived as a ‘ketamine-like’ synaptopathy (64), without features of frank CNS 
inflammation. If NMDAR antibodies do have a causal role in some psychiatric disorders, it is 
therefore possible that the effects represent more of a synaptopathic than a frank 
encephalitic process. 
 
Additionally, the possibility that NMDAR antibodies could play a causal role in some CHR 
cases does not imply that the overall underlying immunology in these cases would be the 
same as in NMDAR encephalitis, a disorder which is characterised by the presence of NR1-
specific intrathecal B cells. Indeed the importance of BBB disruption in determining the 
relevance of peripheral NMDAR antibodies in many human and animal studies of NSAb-
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mediated psychiatric disorders (9, 27, 64)) suggests that intrathecal synthesis may be 
minimal or absent in seropositive subjects with isolated psychiatric presentations. 
 
Given the associations we report between NSAbs and both amygdala enlargement and 
affective symptomatology, it is interesting to note that whereas amygdala volumes are 
reduced in schizophrenia and first episode schizophrenic psychosis, they are increased in 
the first episode of affective psychoses and other nonschizophrenic psychoses (including 
brief psychotic disorder) (65). The increase in amygdala volumes in our NSAb seropositive 
subjects could represent acute inflammation, as is the case in acute limbic encephalitis. 
Importantly, in the post-acute phase of autoimmune encephalitis there is evidence of 
volume loss in these same regions, which is in turn linked to the severity of persisting 
deficits (5, 15, 17). If the neuroanatomical associations of NSAb seropositivity truly 
represent a similar mechanism to that of autoimmune encephalitis, one testable hypothesis 
is that these brain regions will show accelerated atrophy or volume loss at follow-up scans 
in seropositive CHR subjects. 
 
Prüss, Finke and colleagues have highlighted associations between IgA NMDAR antibodies 
and cognitive impairments in multiple clinical contexts (2, 18, 66). In the present study, 6 
CHR subjects had IgA NMDAR antibodies, compared with no HCs. It is thus possible that IgA 
NMDAR antibodies drive the cognitive impairment observed in our seropositive subjects. 
IgM, and many IgAs, are not frequently reported in the CSF, although this may potentially 
reflect a bias towards the measurement of IgG only. While IgA can exist as monomers in 
blood, IgMs are multimerised antibodies, potentially making their crossing of the blood 
brain barrier less likely than IgGs. 
 
We observed that in CHR individuals NMDAR antibody serostatus fluctuates over time. Pan 
and colleagues recently reported similar findings in animals and human subjects (following 
stroke): a majority of individuals remained seronegative, and a minority either remained 
seropositive or acquired de novo antibodies at 1-3 year follow-up (67). What causes these 
fluctuations, and whether they have any direct clinical consequences, has not been 
established (although there is some emerging evidence for chronic stress as a potential 
inducer of NMDAR antibodies). 
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Comparison of cell-based assays 
 
In the largest direct assay comparison reported to date, we found that live CBA detects a 
nine times higher prevalence of IgG NMDAR antibodies in serum than fixed CBA, confirming 
a previous report in a first episode psychosis cohort (23). In this earlier report, even in the 
absence of seropositivity on fixed CBA, these IgG both targeted and were capable of altering 
the surface dynamics of the NMDAR suggesting pathogenic potential.  
 
In total 72.4% of IgG seropositive samples bound hippocampal neurons; this was more true 
of IgG seropositive samples on fixed CBA (91.7%) than on live CBA (58.8%).  This is 
consistent with live CBA potentially detecting antibodies with higher sensitivity than the 
fixed CBA. The fact that in our laboratory not all live CBA-positive samples bound rat 
hippocampal neurons (see also (21)) does not undermine the potential disease-relevance of 
NMDAR IgG seropositivity, particularly as these antibodies have pathogenic potential at the 
level of the NMDAR (22, 23). Immunocytochemistry with cultured neurons, as with all 
assays, has a detection threshold, and this should be understood in the context that CBAs 
overexpress the antigen at the surface but in immunocytochemistry expression levels are 
broadly physiological. Therefore it might be expected that some lower titre samples that are 
positive on live assay will not demonstrate binding to neurons. The observed correlation 
between NMDAR IgG live CBA titre and hippocampal binding intensity is suggestive that live 
CBA is measuring genuine IgG binding, and indeed the live CBA threshold above which 
NMDAR IgG positive samples will reliably bind to neurons appears to be 1:250. 
 
The role of the blood-brain barrier 
 
Ehrenreich and colleagues have stressed that for peripheral NSAbs to be clinically relevant 
there may also need to be disruption of the BBB (64). This has been demonstrated in mice 
with an ApoE-/- haplotype (68) and in humans with a ‘history of neurotrauma’ or obstetric 
complications as medical proxies (9). A parsimonious interpretation is that when the 
integrity of the BBB is compromised, NSAbs have greater access to the CNS and are more 
likely to disrupt brain function (28). However, it is also possible that serum NSAbs are 
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peripheral biomarkers of a central dysfunction that is accompanied by BBB disruption, such 
as neuroinflammation. Consistent with the role of the BBB as proposed by Ehrenreich and 
colleagues, in a supplemental analysis we observed positive associations between S100B 
levels (a widely used proxy for BBB disruption (28, 31)) and symptom scores in subjects who 
were seropositive for NMDAR antibodies on live CBA; these associations were in the 
opposite direction in subjects without detectable serum antibodies. Given the small 
numbers of seropositive subjects however this finding mandates replication in a larger 
sample, potentially with an additional marker of BBB disruption. The ‘gold standard’ of BBB 
quantification in humans is the CSF-serum albumin quotient, which has consistently been 
found to be abnormal in psychosis (28). However this requires a lumbar puncture, which is 
not usually part of the clinical assessment of patients with psychosis, let alone individuals at 
CHR (69). A less invasive method for BBB quantification in these individuals is the use of 
dynamic contrast-enhanced MRI (70).  
 
Antibodies as biomarkers in the CHR state 
 
Separately, or in addition to, the question of the pathogenicity of NMDAR antibodies in the 
CHR state, the present study indicates a potential role for these antibodies as biomarkers of 
poor cognition, depressive symptomatology and/or outcome in the CHR state.  
 
In CHR subjects, severe psychopathology and cognitive impairments, and alterations in 
limbic brain volumes at presentation are associated with an increased risk of later transition 
to psychosis (12-14, 71, 72). Impaired verbal memory performance in CHR individuals is one 
of the strongest cognitive predictors of subsequent transition to psychosis (73, 74). Low IQ 
has also been identified as a predictor of conversion to psychosis in CHR subjects (75), and is 
an established risk factor for psychosis in the general population (76). Our study suggests, 
complementing similar findings in other patient groups (2, 18, 20, 66), that NMDAR 
antibodies may have a role as a biomarker of cognitive impairment in CHR subjects. Since 
we observed that antibody serostatus fluctuates over time, an important question is 
whether cognitive status fluctuates in association with serostatus. This latter might be 
expected if NMDAR antibodies represent state (rather than trait) biomarkers for poor 
cognition: indeed most passive transfer models suggest that the antibody effects are 
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reversible. However a different relationship might be expected if serostatus is in fact a 
marker of poor cognitive performance due to the impact of an as-yet undetermined 
confounder.  
 
In our study, NMDAR antibodies did not predict transition to psychosis, as defined by 
operationalised criteria, or nonremission from the CHR state, despite all but one NMDAR 
IgG seropositive subjects still meeting CHR criteria at follow-up. NMDAR antibody 
seropositivity was however associated with a deterioration in disability-associated 
functioning, short of transition, and indeed greater antibody titre was associated with 
greater deterioration in function, overall suggesting that NMDAR antibody serostatus should 
be further evaluated as a predictive marker of functional outcome. 
 
Limitations 
 
We measured NSAbs in serum. Assessing NSAbs in cerebrospinal fluid (CSF) may provide a 
better way of investigating their role in some autoimmune CNS disorders, but lumbar 
puncture is more invasive and is not usually carried out in CHR subjects. However, while CSF 
NSAbs are important for the diagnosis of autoimmune encephalitis, this does not imply that 
serum NSAbs are irrelevant in psychiatric conditions such as the CHR state. As Castillo-
Gomez and colleagues have demonstrated, in conditions in which antibody production is 
putatively lower than in autoimmune encephalitis the brain may act as 
‘immunoprecipitator’ of CSF NSAbs, and NSAbs may not be detectable in CSF, despite having 
functional consequences in the brain (68). Although we studied a large sample of CHR 
subjects, because only a minority were antibody-positive, the numbers of subjects in some 
of the comparisons was small and hence we did not perform corrections for multiple 
comparisons. We also cannot exclude the possibility that we failed to detect some 
differences because of limited statistical power. This issue may be addressed by pooling 
data from different CHR cohorts, as in the Harmony collaboration  
(https://www.pronia.eu/news-pronia/news-detail/tx_news/initiation-of-the-multi-center-
collaboration-harmony-in-october-copy-1/). 
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Figure legends  
 
Figure 1. NSAb seroprevalence and associations of seropositivity in CHR and HCs – antibodies 
detected using fixed assay. a) Examples of seropositive immunoassays. Top left: fixed CBA 
seropositive for NMDAR antibody IgG (CHR subject); human IgG is labelled green using a fluorescent 
secondary antibody. Top right: immunohistochemistry showing IgG binding to fixed and 
permeabilised rat hippocampus (CHR subject seronegative for other specific antigenic targets); 
human IgG is labelled green using a fluorescent secondary antibody. Bottom left: IgG from CHR 
subject showing strong binding to cultured hippocampal neurons (score 3 out of 4); human IgG is 
labelled green using a fluorescent secondary antibody (AlexaFluor 488 mouse anti-human IgG1; 
Invitrogen) (left and right) and hippocampal neurons are labelled red using mouse MAP2 antibodies 
(Monoclonal-Anti-MAP2, clone HM-2, Sigma Aldrich) (right). Scalebar = 25um. b) Confocal 
microscope image of IgG from CHR subject showing strong binding to cultured hippocampal 
neurons. Cell nuclei are DAPI-labelled; human IgG is labelled green using a fluorescent secondary 
antibody (AlexaFluor 488 mouse anti-human IgG1; Invitrogen) and hippocampal neurons are labelled 
red using mouse MAP2 antibodies (Monoclonal-Anti-MAP2, clone HM-2, Sigma Aldrich). Scalebar = 
25um. c) Distribution of antigen target by group (note percentages are of the totality of samples 
tested). d) Distribution of antibody isotype by group. e) Distribution of antibody titre by group and 
assay type; IgG = green, IgA = red, IgM = blue.  
 
Figure 2: NMDAR IgG seroprevalence and associations of seropositivity – antibodies detected using 
live assay. a) Representative example of NMDAR IgG positive live CBA. Human IgG is labelled red 
using a fluorescent secondary antibody (AlexaFluor 568 goat anti-mouse IgG (H+L); Invitrogen) and 
shown binding to cells that co-express eGFP (green). Scalebar = 25um.  b) Distribution of NMDAR IgG 
titre by group and assay type (fixed vs live assay).  
 
 
Table 1: Demographic/basic clinical information and NSAb serostatus by group  
 
*data available for 365 of 370 subjects 
**Adjusted for BMI, gender, age, ethnicity and smoking status 
Abbreviations: CHR: clinical high risk, HC: healthy control, CBA: cell-based assay, S100B: S100 calcium-
binding protein B, CRP: C-reactive protein, NMDAR: N-methyl-d-aspartate receptor. 
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Table 2: Demographic/basic clinical information by NSAb serostatus 
 
*data available for 365 of 370 subjects 
**Statistic adjusted for BMI, gender, age, ethnicity and smoking status 
Abbreviations: CBA: cell-based assay, S100B: S100 calcium-binding protein B, CRP: C-reactive protein, 
NMDAR: N-methyl-d-aspartate receptor, BMI: body mass index. 
 
Table 3: Cognitive function and psychopathology scores by NMDAR antibody serostatus (descriptive 
means shown with F and p values from ANOVA). Numbers in brackets under variable names are the 
number of seropositive subjects and seronegative subjects for whom data were available for that 
variable. BPRS total score excluded from analysis due to heteroscedasticity. 
 
 
  Total CHR cohort 
(n=254) 
Total HC cohort (n=116) p
Age  22.70 ± 5.00 (range 14 
to 45) 
23.54 ± 3.38 (range 17 
to 34) 
0.057
Sex [M: n (%)] 136 (53.5) 60 (51.7) 0.822
Ethnicity [n (%)] White 178 (70.4), Black 
22 (8.7), Other 53 (20.9) 
White 76 (65.5), Black 
24 (20.7), Other 16 
(13.8) 
0.003
Smoker* [n (%)] 133 (53.4) 31 (26.7) <0.001
BMI 24.31 ± 5.30 23.70 ± 4.44 0.288
Current antipsychotic use 
[n (%)] 
24 (9.4) 0 (0) <0.001
S100B (ug/L)** 0.040 ± 0.049 0.050 ± 0.071 0.833
CRP (mg/L)** 1.23 ± 1.08 
 
0.95 ± 0.95
 
0.048
Any antibody (fixed CBA) 
[n (%)] 
21 (8.3) 6 (5.2) 0.390 
IgG [n (%)] 9 (3.5) 4 (3.4) 1.000 
IgA [n (%)] 8 (3.1) 1 (0.9) 0.283 
IgM [n (%)] 5 (2.0) 1 (0.9) 0.670 
NMDAR antibody (fixed 
CBA) [n (%)] 
11 (4.3) 2 (1.7) 0.360 
NMDAR IgG [n (%)] 1 (0.4) 1 (0.9) 0.529 
NMDAR IgA [n (%)] 6 (2.4) 0 (0.0) 0.183 
NMDAR IgM [n (%)] 4 (1.6) 1 (0.9) 1.000 
NMDAR IgG (live CBA) [n 
(%)] 
13 (5.1) 6 (5.2) 1.000
 
Table 1: Demographic/basic clinical information and NSAb serostatus by group  
 
*data available for 365 of 370 subjects 
**Adjusted for BMI, gender, age, ethnicity and smoking status 
Abbreviations: CHR: clinical high risk, HC: healthy control, CBA: cell-based assay, S100B: S100 calcium-binding protein B, CRP: C-reactive protein, NMDAR: N-
methyl-d-aspartate receptor. 
 
 
 
 
  Any antibody 
negative 
(n=343) 
Any antibody 
positive (fixed 
CBA) (n=27) 
p NMDAR 
antibody 
negative 
(fixed CBA) 
(n=357) 
NMDAR 
antibody 
positive (fixed 
CBA) (n=13) 
p NMDAR 
antibody 
negative (live 
CBA) (n=351) 
NMDAR 
antibody 
positive (live 
CBA) (n=19) 
p 
Age 23.01 ± 4.60 22.33 ± 4.13 0.458 22.97 ± 4.57 22.69 ± 4.57 0.829 22.92 ± 4.50 23.79 ± 5.73 0.418
Sex [M: n (%)] 178 (51.9) 18 (66.7) 0.163 187 (52.4) 9 (69.2) 0.270 188 (53.6) 11 (57.9) 0.330 
Ethnicity [n (%)] White 231 
(67.5) Black 45 
(13.2) Other 
66 (19.3) 
White 23 
(85.2) Black 1 
(3.7) Other 3 
(11.1) 
0.148 White 44 
(68.5) Black 
45 (12.6) 
Other 67 
(18.8) 
White 10 
(76.9) Black 1 
(7.7) Other 2 
(15.4) 
0.797 White 243 
(69.4) 
Black 43 
(12.3) 
Other 64 
(18.3) 
White 11 
(57.9) 
Black 3 (15.8) 
Other 5 (26.3) 
0.563 
Smoker* [n (%)] 155 (45.9) 9 (33.3) 0.233 160 (45.5) 4 (30.8) 0.398 155 (44.8) 9 (47.4) 0.826
BMI 24.17 ± 4.98 23.19 ± 5.55 0.370 24.07 24.94 0.591 24.12 ± 5.02 23.82 ± 5.10 0.815
Current 
antipsychotic 
use [n (%)] 
21 (6.1) 3 (11.1) 0.403 22 (6.2) 2 (15.4) 0.203 22 (6.3) 2 (10.5) 0.463
CRP (mg/L)** 1.14 ± 1.04 
 
1.12 ± 1.21
 
0.991 1.14 ± 1.04
 
1.28 ± 1.41  0.925 1.14 ± 1.05
 
1.17 ± 0.94
 
0.506 
S100B (ug/L)** 0.043 ± 0.058 
 
0.038 ± 0.033
 
0.613 0.043 ± 0.057
 
0.04 ± 0.043
 
 0.994 0.043 ± 0.058
 
0.037 ± 0.031
 
0.783 
 
 
Table 2: Demographic/basic clinical information by NSAb serostatus 
 
*data available for 365 of 370 subjects 
**Statistic adjusted for BMI, gender, age, ethnicity and smoking status 
Abbreviations: CBA: cell-based assay, S100B: S100 calcium-binding protein B, CRP: C-reactive protein, NMDAR: N-methyl-d-aspartate receptor, BMI: body mass 
index. 
 
 
 
Antibody 
positive 
Antibody 
negative 
F (serostatus) p (serostatus) 
 
NMDAR ANTIBODY (IgG, IgA, IgM; FIXED ASSAY)  
AVLT IR total
(7:160)
52.00 ± 
13.79 
63.06 ± 
11.90 
 
4.817 0.030
AVLT IR total (CAARMS adjusted)
(5:127)
45.80 ± 
10.69 
62.50 ± 
11.90 
 
7.651 0.007
WAIS estimated total IQ
(9:222)
84.22 ± 
20.35 
 
98.71 ± 
16.90 
 
6.687 0.010
WAIS estimated total IQ (CAARMS adjusted)
(7:182)
83.29 ± 
21.62 
 
100.32 ± 
16.86 
 
7.134 0.008
CAARMS total
(9:198)
49.00 ± 
16.17 
 
49.49 ±
15.00 
 
0.001  0.981
BPRS positive sx
(11:224)
14.91 ± 
5.43 
 
13.55 ± 4.54
 
0.731 0.393
SANS
(9:210)
20.44 ± 
15.30 
 
15.53 ± 
11.74 
 
1.074  0.301
YMRS
(11:225)
4.27 ± 
5.35 
 
4.00 ± 4.79
 
0.03  0.957
MADRS
(11:230)
20.91 ± 
12.98 
 
18.69 ± 9.16
 
0.650  0.421
 
NMDAR ANTIBODY (IgG; LIVE ASSAY)  
AVLT IR total
(9:158)
58.00 ± 
13.90 
62.86 ± 
12.03 
 
0.929 0.337 
AVLT IR total (CAARMS adjusted)
(9:123)
58.00 ± 
13.90 
62.15 ± 
12.13 
 
0.826 0.365
WAIS estimated total IQ
(12:219)
95.00 ± 
19.98 
 
98.32 ± 
17.10 
 
0.067 0.796
WAIS estimated total IQ (CAARMS adjusted)
(12:177)
95.00 ± 
19.98 
 
100.01± 
17.11 
 
0.353 0.553
CAARMS total
(13:194)
51.00 ± 
11.90 
 
49.37 ± 
15.21 
 
 0.197  0.657 
BPRS positive sx
(13:222)
14.62 ± 
4.82 
 
13.56 ± 4.57 
 
 0.683  0.409  
SANS
(13:206)
15.31 ± 
11.39 
 
15.76 ± 
11.96 
 
0.058 0.810
YMRS
(12:224)
6.50 ± 
5.16 
 
3.89 ± 4.76
 
3.179 0.076
MADRS
(13:228)
23.69 ± 
9.05 
 
18.51 ± 9.30
 
3.847 0.051
 
Table 3: Cognitive function and psychopathology scores by NMDAR antibody serostatus (descriptive means shown with F and p values from ANOVA). Numbers in 
brackets under variable names are the number of seropositive subjects and seronegative subjects for whom data were available for that variable. BPRS total score 
excluded from analysis due to heteroscedasticity. 
 
Abbreviations: NMDAR: N-methyl-d-aspartate receptor, AVLT: Rey Auditory Verbal Learning Task, IR: immediate recall, CAARMS: Comprehensive Assessment of At-
Risk Mental States, WAIS: Wechsler Adult Intelligence Scale III, BPRS: Brief Psychiatric Rating Scale, SANS: Scale for the Assessment of Negative Symptoms, YMRS: 
Young Mania Rating Scale, MADRS: Montgomery-Asberg Depression Rating Scale  
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